Kolltan Pharmaceuticals, Inc.;Salk Institute for Biological Studies
发明人:
Greg E. Lemke,Lawrence C. Fritz,Benedikt Vollrath,Carla V. Rothlin
申请号：
US15270813
公开号：
US20170129947A1
申请日:
2016.09.20
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.
